Can I read Tumor-derived Erythropoietin Acts as an Immunosuppressive Switch in Cancer Immunity on EtoBox?

Tumor-derived Erythropoietin Acts as an Immunosuppressive Switch in Cancer Immunity by Bo Yu, Ryan Lee, Catherine Zhang, Xiuli An, Jayakumar Rajadas, Nathan E. Reticker-Flynn, is a book available to read on EtoBox.

What is Tumor-derived Erythropoietin Acts as an Immunosuppressive Switch in Cancer Immunity about?

INTRODUCTION: Cancer patients with inflamedhepatocellular carcinoma (HCC) with eithereither through genetic deletion or macrophage(T cell–rich) tumors, indicative of an active antian inflamed or a noninflamed tumor microtargeted small interfering RNA treatment—tumor immune response, often benefit fromenvironment (TME). Notably, elevated plasmasignificantly inhibited noninflamed tumorimmune checkpoint blockade (ICB) therapy.erythropoietin (EPO) and splenomegaly weregrowth, even leading to spontaneous regressionHowever, despite the presence of tumormutationsobserved exclusively in noninflamed tumorof some established tumors. This effect wasthat should theoretically trigger an immune reprimarily driven by a robust CD8+ TEM cell remodels, independent of tumor size and withoutsponse, most patients have noninflamed (T cell–signs of anemia. EPO, a glycoprotein hormonesponse, which synergized with ICB. A similardeprived) tumors and do not benefit from ICB.known for stimulating red blood cell production,therapeutic synergy was also observed in esThese noninflamed tumors are typically repletehas recently been implicated in other biologicaltablished noninflamed tumors treated withwith i

Author

Bo Yu, Ryan Lee, Catherine Zhang, Xiuli An, Jayakumar Rajadas, Nathan E. Reticker-Flynn,

Published

2025

Language

EN